ACR Convergence 2024 Archives - Page 5 of 182

Abstract Number: 2598

p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Abstract Number: 2002

Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Abstract Number: 0323

Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1816

Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages
Abstract Number: 0090

Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus
Abstract Number: 2161

Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Abstract Number: 2188

Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis
Abstract Number: 1172

Participation in Baseball/Softball Associates with Increased Risk for Knee Pain and Osteoarthritis as an Adult: Data from the Osteoarthritis Initiative
Abstract Number: 0301

Path to Diagnosis in Familial Mediterranean Fever (FMF)
Abstract Number: 1234

Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration
Abstract Number: 1318

Patient Anxiety, Fear, and Kinesiophobia: Challenges Shared by UK Physiotherapists in Managing Polymyalgia Rheumatica – Findings from a Qualitative Study
Abstract Number: 2337

Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Abstract Number: 2488

Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
Abstract Number: 2101

Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis
Abstract Number: 0558

Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Abstract Number: 0375

Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
Abstract Number: 2095

Patient Perceptions of an Osteoarthritis Management Program at a Midwest Medical Center
Abstract Number: 1232

Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Abstract Number: 1538

Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Abstract Number: 0534

Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Abstract Number: 0356

Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Abstract Number: 2360

Patient Selection and Treatment Outcomes Using Preliminary Data-driven Definition versus the Established ASAS Definition of a Positive MRI of the Sacroiliac Joint in axSpA: Post-hoc Analysis from COAST-X
Abstract Number: 1951

Patient-Reported Barriers to Care Across Pediatric Rheumatology Patients at a Tertiary Academic Medical Center
Abstract Number: 1915

Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting
Abstract Number: 1249

Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Abstract Number: 1919

Patient-reported Social Risk Factor Screening Among Rheumatology Outpatients
Abstract Number: 1473

Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Abstract Number: 2265

Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Abstract Number: 1939

Patient’s Satisfaction with a Telerheumatology Program in a Remote Rural Area of Northern Pakistan
Abstract Number: 0678

Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Abstract Number: 2336

Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
Abstract Number: 1470

Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
Abstract Number: 0132

Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Abstract Number: 0365

Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease
Abstract Number: 0687

Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease
Abstract Number: 1253

Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Abstract Number: 0677

Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Abstract Number: 1207

Patterns of Shared Variation in Knee Ultrasound for Osteoarthritis: A Machine Learning Approach
Abstract Number: 0499

PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Abstract Number: 1105

PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Abstract Number: 2182

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Abstract Number: 2175

Pediatric Rheumatology Clinic Referral Patterns at a Large Midwestern Center
Abstract Number: 2195

Pediatric Rheumatology Graduation: A One-Way Bridge to Adult Care?
Abstract Number: 1897

People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
Abstract Number: 0892

Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Abstract Number: 1405

Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Abstract Number: 1001

Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis
Abstract Number: 2384

Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
Abstract Number: 1015

Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Abstract Number: 1724

Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis
Abstract Number: L04

Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images
Abstract Number: 1438

Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study
Abstract Number: 1740

Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety
Abstract Number: 0118

Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Abstract Number: 2444

Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
Abstract Number: 2062

Performance of the Patient Self-Assessment Tools for Cutaneous Dermatomyositis: Patient CDASI and Rash Mapping
Abstract Number: 0612

Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Abstract Number: 0265

Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Abstract Number: 2394

Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis
Abstract Number: 0799

Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Abstract Number: 1655

Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Target for Osteoarthritis
Abstract Number: 1617

Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Abstract Number: 1369

Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Abstract Number: L02

Persistent Articular Infection and Host Reactive Responses Contribute to Brucella-Induced Spondyloarthritis in SKG Mice
Abstract Number: 2088

Personalized Prediction of Pain and Function for Knee Osteoarthritis Patients 1 Year After Total Knee Arthroplasty Using Machine Learning
Abstract Number: 0890

Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome
Abstract Number: 2590

Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis
Abstract Number: 2134

PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo
Abstract Number: 2294

Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Abstract Number: 1016

Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Abstract Number: 0672

Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Abstract Number: 1085

Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Abstract Number: 0384

Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Abstract Number: 1005

Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Abstract Number: 0303

Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Abstract Number: 0108

Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Abstract Number: 0014

Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Abstract Number: 2054

Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Abstract Number: 2545

Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Abstract Number: 1175

Physical Activity and Symmetry Following Total Knee Arthroplasty:Results of an Exploratory Trial
Abstract Number: 1302

Physician Knowledge, Attitudes and Perceived Barriers to Recommending the Recombinant Varicella Zoster Vaccine
Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Abstract Number: 1413

Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome
Abstract Number: 0182

Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Abstract Number: 0350

Piloting an Adaptation of the Making It Work Program for Systemic Sclerosis: Promising Effects on Job Related Self-efficacy and Risk of Work Disability
Abstract Number: 2109

Pincer Grip and Metacarpophalangeal Patterns Emerge as New Phenotypes of Hand Osteoarthritis Using a Data Driven Approach: Data from the Osteoarthritis Initiative
Abstract Number: 0428

Placental Characteristics in Systemic Lupus Erythematosus Pregnancies Resulting in Small for Gestational Age Infants
Abstract Number: 1702

Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Abstract Number: 0419

Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Abstract Number: 0468

Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
Abstract Number: 0826

Plasma Exchange for Severe Alveolar Hemorrhage in ANCA-Associated Vasculitis: Emulation of a Target Trial
Abstract Number: 0607

Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Abstract Number: 0113

Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Abstract Number: 2601

Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus
Abstract Number: 1112

Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)
Abstract Number: 2068

Poloxamers 188 & 182 Are Effective in Repairing the Membrane Resealing Defect in Myositis
Abstract Number: 2504

Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Abstract Number: 2457

Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Abstract Number: 2618

Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 1391

Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis
Abstract Number: 2130

Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Abstract Number: 1978.5

Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Abstract Number: 1839

PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Abstract Number: 1077

Pragmatic Quantitative Rheumatologist 0–10 Visual Numeric Scale Estimates of Inflammation, Damage, and Patient Distress Have Face Validity and May Be as Informative as Formal 28 Joint Counts in Rheumatoid Arthritis
Abstract Number: 1247

Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Abstract Number: 0010

Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Abstract Number: 1751

Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells
Abstract Number: 0018

Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Abstract Number: 0008

Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Abstract Number: 1841

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Abstract Number: 0002

Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
Abstract Number: 0011

Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Abstract Number: 0013

Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Abstract Number: 2400

Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Abstract Number: 0559

Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Abstract Number: 0984

Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach
Abstract Number: 0225

Prediction of Response to Therapies and Flares Based on Ultrasound Findings at Baseline in Psoriatic Arthritis: An Analysis on a Joint Level
Abstract Number: 0613

Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort
Abstract Number: 2020

Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Abstract Number: 0621

Predictive Parameters of Disease-related Damage Accrual in Patients with Systemic Lupus Erythematosus: A Machine Learning Analysis
Abstract Number: 2349

Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
Abstract Number: 0641

Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Abstract Number: 1518

Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Abstract Number: 1451

Predictors and Patterns of Fragility Fracture in an Observational Cohort of Patients with Psoriatic Arthritis
Abstract Number: 1670

Predictors of 6-Minute Walk Test Performance in Adults with Arthritis
Abstract Number: 0990

Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Abstract Number: 2553

Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Abstract Number: 1587

Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
Abstract Number: 1482

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Abstract Number: 2354

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Abstract Number: 2679

Predictors of Fracture in SLE: A Longitudinal Cohort Study
Abstract Number: 0332

Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Abstract Number: 2163

Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Abstract Number: 1004

Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Abstract Number: 1759

Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
Abstract Number: 0691

Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study
Abstract Number: 0333

Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
Abstract Number: 2325

Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Abstract Number: 2322

Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
Abstract Number: 1487

Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Abstract Number: 0440

Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Abstract Number: 0447

Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Abstract Number: 0434

Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Abstract Number: 2439

Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
Abstract Number: 1666

Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement
Abstract Number: 2170

Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)
Abstract Number: 0703

Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Abstract Number: 0376

Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Abstract Number: 1549

Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Abstract Number: 1536

Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
Abstract Number: 2053

Presence of ANA to Development of Rheumatic Diseases
Abstract Number: 0552

Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
Abstract Number: 2205

Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Abstract Number: 2554

Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska
Abstract Number: 0619

Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
Abstract Number: 1156

Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 2461

Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy
Abstract Number: 2520

Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Abstract Number: 1200

Prevalence and Joint Involvement Patterns of Erosive and Non-erosive Hand Osteoarthritis in the General Population in China
Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Abstract Number: 0159

Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Abstract Number: 1363

Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)
Abstract Number: 0415

Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
Abstract Number: 1565

Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Abstract Number: 2321

Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
Abstract Number: 2615

Prevalence of and Factors Associated with Developing Long COVID Among Patients with Autoimmune Rheumatic Diseases: A Retrospective Cohort Analysis of National U.S. Data
Abstract Number: 2657

Prevalence of Anxiety, Depression, and Fatigue in Patients with Rheumatic Diseases: A Cross-Sectional Study of 1014 Cases
Abstract Number: 0407

Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India
Abstract Number: 0570

Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Abstract Number: 1434

Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
Abstract Number: 1889

Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States
Abstract Number: 0795

Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Abstract Number: 0648

Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Abstract Number: 1879

Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Abstract Number: 2090

Prevalence of Steatotic Liver Disease and Liver Fibrosis Among Patients with Osteoarthritis (OA)
Abstract Number: 1435

Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment
Abstract Number: 1563

Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
Abstract Number: 2672

Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial
Abstract Number: 2147

Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients
Abstract Number: 1292

Primary Care Provider Educational Tool to Improve Osteoarthritis Management in the Primary Care Setting
Abstract Number: 2222

Primary Lung Involvement in Early Rheumatoid Arthritis
Abstract Number: 0764

Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Abstract Number: 0062

Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts
Abstract Number: 2247

Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
Abstract Number: 2541

Probiotic Modulation of Gut Microbiota Mitigates Early Rheumatoid Arthritis Progression: Insights from Pre-Clinical Models
Abstract Number: 0895

Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis
Abstract Number: 0015

Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Abstract Number: 0088

Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Abstract Number: 1624

Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
Abstract Number: 2048

Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
Abstract Number: 2451

Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Abstract Number: 1098

Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Abstract Number: 0695

Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Abstract Number: 0683

Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement
Abstract Number: 0704

Progression of Global Longitudinal Strain and Identification of Left Ventricular Dysfunction in Systemic Sclerosis Patients
Abstract Number: 2470

Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
Abstract Number: 0317

Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Abstract Number: 0340

Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease
Abstract Number: 1540

Project HOPE: HydrOxychloroquine Adherence ProjEct
Abstract Number: 1598

Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Abstract Number: L05

Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Abstract Number: 2396

PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Abstract Number: 1729

Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Abstract Number: 0283

Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Abstract Number: 2065

Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Abstract Number: 0727

Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study
Abstract Number: 0700

Prospective Evaluation of Capillaroscopy in Healthy Children
Abstract Number: 1088

Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout
Abstract Number: 2310

Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease
Abstract Number: 2193

Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C
Abstract Number: 1531

Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Abstract Number: 0252

Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Abstract Number: 0104

Proteomic Analysis Identifies Neutrophil Defensin 1 as a Biological Marker for Antiphospholipid Syndrome
Abstract Number: 0045

Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins
Abstract Number: 1825

Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Abstract Number: 0899

Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Abstract Number: 2081

Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies
Abstract Number: 0906

Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers
Abstract Number: 0416

Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis
Abstract Number: 0968

Proteomic, Transcriptomic, and Functional Characterization of Circulating Extracellular Vesicles in Progressive Scleroderma Interstitial Lung Disease
Abstract Number: 1383

Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2564

Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study
Abstract Number: 2332

PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
Abstract Number: 0156

Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Abstract Number: 0067

Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Abstract Number: 1883

Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Abstract Number: 1528

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Abstract Number: 0993

Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis
Abstract Number: 2234

Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Abstract Number: 1689

Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Abstract Number: 1140

Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis